Pharma and vaccine companies at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
30 pharma and vaccine companies are at IDWeek 2026 — 182 presentations on the program and 23 with a booth in the exhibit hall. Most represented: Pfizer (28 on the program), Gilead Sciences (21 on the program), Merck (17 on the program). 26 of them have their own page in this guide. As of Oct 16, 2026.
Topic
Top represented
Showing 1–1 of 30 organizations
| Organization | IDWeek 2026 Attendance |
|---|---|
Pfizer New York, NY | |
Global pharmaceutical company whose infectious disease portfolio includes pneumococcal, RSV and COVID-19 vaccines and the COVID-19 antiviral Paxlovid. | Booth Exhibiting at Booth 1024, BS 6, BS 7 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 7:00am–8:00am Real-World Evidence on Adult Respiratory Vaccines and Select Acute and Post-Acute Outcomes Associated With Respiratory Infections VaccinesRespiratory infections and COVID-19 Industry Thu Oct 22 11:15am–12:00pm Helping to Protect Eligible Adult Patients Against Pneumococcal Disease Caused by Medically Important Serotypes VaccinesRespiratory infections and COVID-19 Poster Thu Oct 22 12:15pm–1:30pm Clostridioides difficile incidence among adults with underlying health conditions in the United States, 2018 – 2024 Poster Thu Oct 22 12:15pm–1:30pm Increasing National Burden of Clostridioides difficile Infection Cases, Hospitalizations, and Deaths in the United States, 2017-2023 Industry Thu Oct 22 1:15pm–2:00pm The Evolving COVID-19 Antiviral Landscape: Insights from Pfizer's Development Pipeline Antimicrobials, resistance and stewardshipRespiratory infections and COVID-19 Talk Thu Oct 22 3:51pm–4:03pm Talk Thu Oct 22 4:03pm–4:15pm Industry Fri Oct 23 10:15am–11:00am Help Protect Adults Who Are at Risk With a Respiratory Syncytial Virus (RSV) Vaccine VaccinesRespiratory infections and COVID-19 Industry Fri Oct 23 11:15am–12:00pm Sticking it to COVID-19: Updates on the Disease and a Vaccine Option from BioNTech and Pfizer VaccinesRespiratory infections and COVID-19 Poster Fri Oct 23 12:15pm–1:30pm Impact of Lyme Disease on Patient-Reported Outcomes in the United States: A Prospective Survey Study Talk Fri Oct 23 3:27pm–3:39pm Improved Virologic Control in Severely Immunocompromised (SIC) Adults with COVID-19 Receiving Extended Duration Paxlovid Therapy Antimicrobials, resistance and stewardshipTransplant and immunocompromised hosts Talk Fri Oct 23 4:15pm–4:27pm Industry Fri Oct 23 6:30pm–7:30pm COVID-19, an Evolving Disease - The ACE-2 Narrative Respiratory infections and COVID-19 Industry Sat Oct 24 10:30am–10:50am Talk Sat Oct 24 11:06am–11:18am Safety and Immunogenicity of LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Children 5–11 Years of Age VaccinesRespiratory infections and COVID-19 Talk Sat Oct 24 11:18am–11:30am Poster Sat Oct 24 12:15pm–1:30pm 13-valent pneumococcal conjugate vaccine: 3-year impact on risk of major adverse cardiovascular events among Medicare beneficiaries in the United States Poster Sat Oct 24 12:15pm–1:30pm 20-valent pneumococcal conjugate vaccine: Impact and effectiveness against all-cause outcomes among the general population of US older adults by age group, regardless of prior pneumococcal vaccine history Poster Sat Oct 24 12:15pm–1:30pm A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b2 RNA-based Variant-adapted Vaccine Candidate (LP.8.1) against SARS-CoV-2 in Participants 12 through 64 Years of Age Considered at Higher Risk of Severe COVID-19 and Participants ≥ 65 Years of Age Poster Sat Oct 24 12:15pm–1:30pm Acute COVID-19 Symptom Burden Among U.S. Adults During the 2025–2026 Respiratory Disease Season: Results from a Nationwide Study Poster Sat Oct 24 12:15pm–1:30pm Acute Symptom Burden of Influenza Infection Among US Adults During the 2025-2026 Respiratory Season: A Nationwide Prospective Study Poster Sat Oct 24 12:15pm–1:30pm Asthma and COPD Exacerbations Before and After the Emergence of SARS-CoV-2 in the United States Poster Sat Oct 24 12:15pm–1:30pm COVID-19 Symptom Burden and Comorbidity Profile among US Adults at High Risk for Severe COVID-19 Poster Sat Oct 24 12:15pm–1:30pm Comparison of Healthcare Resource Utilization and Costs of Respiratory Syncytial Virus Infection between Vaccinated and Unvaccinated US Medicare Beneficiaries Poster Sat Oct 24 12:15pm–1:30pm Cost Effectiveness of the Pfizer Pentavalent MenABCWY Vaccine Administered With an Extended Dosing Interval: Public Health and Economic Outcomes With a Novel Two-Dose Adolescent Meningococcal Vaccination Strategy Poster Sat Oct 24 12:15pm–1:30pm Crowded Fall Vaccination in Retail Pharmacy Setting among US Adults Aged 50 years and Older Poster Sat Oct 24 12:15pm–1:30pm Efficacy of Ibuzatrelvir on Sustained Overall Symptom Alleviation: Post-hoc Analysis from a Phase 2b Randomized Clinical Trial Poster Sat Oct 24 12:15pm–1:30pm Estimating the Incidence of RSV-Attributable Respiratory and Cardiorespiratory Hospitalizations among High-Risk Patients in Select High- and Middle-Income Countries Poster Sat Oct 24 12:15pm–1:30pm Impact of COVID-19 on Health-Related Quality of Life and Work Productivity Among US Adults in the 2025-2026 Respiratory Season: Results from a Nationwide Longitudinal Study Poster Sat Oct 24 12:15pm–1:30pm Inpatient Burden of COVID-19 Among Individuals with and without Chronic Kidney Disease in Japan Poster Sat Oct 24 12:15pm–1:30pm Long COVID in High-Risk Pediatric Subpopulations Poster Sat Oct 24 12:15pm–1:30pm Multisystem Incident Post-COVID Conditions in Individuals with Pre-existing Cardiometabolic Disease Poster Sat Oct 24 12:15pm–1:30pm Number Needed to Vaccinate for Pediatric Pneumococcal Conjugate Vaccines: How Dynamic Transmission Modeling Reshapes Comparative Estimates for PCV20 and PCV15 Poster Sat Oct 24 12:15pm–1:30pm Patient Characteristics Underlying COVID-19 Antiviral Prescribing decisions in Primary, Urgent, and Emergency Care Settings Poster Sat Oct 24 12:15pm–1:30pm Pneumococcal Conjugate Vaccine Series Completion Among Children with Medicaid Insurance in Selected States of the United States, 2021-2023 Poster Sat Oct 24 12:15pm–1:30pm Pregnancy and Infant Outcomes Following Exposure to PAXLOVID: Interim Results from A Post-Authorization Safety Study Poster Sat Oct 24 12:15pm–1:30pm Public Health Impact and Cost-Effectiveness of Revaccination with Bivalent Respiratory Syncytial Virus Prefusion F Vaccination Among Immunocompromised Adults in the United States Poster Sat Oct 24 12:15pm–1:30pm Public Health and Economic Impact of Complementary Infant Immunization Strategies against Respiratory Syncytial Virus (RSV) in Canada Given Shifting Seasonal Patterns Poster Sat Oct 24 12:15pm–1:30pm RSV Burden in Adults in Emerging Market Countries, a Systematic Review and Modelling Analysis Poster Sat Oct 24 12:15pm–1:30pm RSV Testing Rates by Comorbidities and Age Groups among Adults Hospitalized for Lower Respiratory Infections in the United States, September 2024 to April 2025 Poster Sat Oct 24 12:15pm–1:30pm RSV Testing Trends among Adults Hospitalized for Respiratory Infections in the United States, September 2019 to April 2025 Poster Sat Oct 24 12:15pm–1:30pm Real-world Effectiveness of Nirmatrelvir-Ritonavir in Reducing Severe COVID-19 Outcomes by Age Groups in Canada Poster Sat Oct 24 12:15pm–1:30pm Stability of Risk Condition-Associated Incidence Rate Ratios for Pediatric Infectious Disease Across Episode Gap Definitions Poster Sat Oct 24 12:15pm–1:30pm The Burden of Human Parainfluenza Virus (PIV) in Adults: A Systematic Literature Review and Meta-analysis Poster Sat Oct 24 12:15pm–1:30pm The Burden of Influenza Infection on Health-Related Quality of Life and Work Productivity Among US Adults During the 2025-2026 Respiratory Season: A Nationwide Prospective Study Poster Sat Oct 24 12:15pm–1:30pm Why Are Only a Minority of Eligible Patients Prescribed COVID-19 Antivirals? |
Instantly find 20 buyers from pharma and vaccine companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse IDWeek 2026 by
Organization type
Topic
- Antimicrobials, resistance and stewardship 420
- Vaccines 122
- Diagnostics and diagnostic stewardship 247
- HIV, sexually transmitted infections and viral hepatitis 256
- Infection prevention and healthcare epidemiology 292
- Transplant and immunocompromised hosts 173
- Respiratory infections and COVID-19 163
- Global and public health 211
Exhibit hall
Everyone
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction